808 related articles for article (PubMed ID: 19559476)
41. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.
Simarro PP; Franco J; Diarra A; Postigo JA; Jannin J
Parasitology; 2012 Jun; 139(7):842-6. PubMed ID: 22309684
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Toxicity of Fexinidazole and Nifurtimox Plus Eflornithine in the Treatment of African Trypanosomiasis: A Systematic Review.
Hidalgo J; Ortiz JF; Fabara SP; Eissa-Garcés A; Reddy D; Collins KD; Tirupathi R
Cureus; 2021 Aug; 13(8):e16881. PubMed ID: 34513456
[TBL] [Abstract][Full Text] [Related]
43. The rise and fall of sleeping sickness.
Barrett MP
Lancet; 2006 Apr; 367(9520):1377-8. PubMed ID: 16650633
[No Abstract] [Full Text] [Related]
44. Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017.
Wang X; Ruan Q; Xu B; Gu J; Qian Y; Chen M; Liu Q; Lu Q; Zhang W
Emerg Infect Dis; 2018 Feb; 24(2):400-404. PubMed ID: 29350158
[TBL] [Abstract][Full Text] [Related]
45. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
Sokolova AY; Wyllie S; Patterson S; Oza SL; Read KD; Fairlamb AH
Antimicrob Agents Chemother; 2010 Jul; 54(7):2893-900. PubMed ID: 20439607
[TBL] [Abstract][Full Text] [Related]
46. Killer coma: the evolving story of sleeping sickness treatment.
Lancet; 2010 Jan; 375(9709):93. PubMed ID: 20109869
[No Abstract] [Full Text] [Related]
47. Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2-3 trial.
Kande Betu Kumesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Nganzobo Ngima P; Mahenzi Mbembo H; Fina Lubaki JP; Lumeya Vuvu S; Kuziena Mindele W; Ilunga Wa Kyhi M; Mandula Mokenge G; Kaninda Badibabi L; Kasongo Bonama A; Kavunga Lukula P; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet Glob Health; 2022 Nov; 10(11):e1665-e1674. PubMed ID: 36179736
[TBL] [Abstract][Full Text] [Related]
48. African sleeping sickness in the United States. Successful treatment with eflornithine.
Petru AM; Azimi PH; Cummins SK; Sjoerdsma A
Am J Dis Child; 1988 Feb; 142(2):224-8. PubMed ID: 3124603
[TBL] [Abstract][Full Text] [Related]
49. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA
Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099
[TBL] [Abstract][Full Text] [Related]
50. Human African trypanosomiasis in Angola: clinical observations, treatment, and use of PCR for stage determination of early stage of the disease.
Truc P; Lando A; Penchenier L; Vatunga G; Josenando T
Trans R Soc Trop Med Hyg; 2012 Jan; 106(1):10-4. PubMed ID: 22093811
[TBL] [Abstract][Full Text] [Related]
51. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness.
Khonde N; Pépin J; Mpia B
Trans R Soc Trop Med Hyg; 1997; 91(2):212-3. PubMed ID: 9196773
[TBL] [Abstract][Full Text] [Related]
52. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis.
Franco JR; Simarro PP; Diarra A; Ruiz-Postigo JA; Samo M; Jannin JG
Res Rep Trop Med; 2012; 3():93-101. PubMed ID: 30100776
[TBL] [Abstract][Full Text] [Related]
53. Randomized, controlled trial of treatments for second-stage sleeping sickness.
Woodrow CJ; Abel PM; Krishna S
J Infect Dis; 2007 Aug; 196(4):650-1. PubMed ID: 17624857
[No Abstract] [Full Text] [Related]
54. Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis.
Mpia B; Pépin J
Trop Med Int Health; 2002 Sep; 7(9):775-9. PubMed ID: 12225509
[TBL] [Abstract][Full Text] [Related]
55. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda.
Priotto G; Fogg C; Balasegaram M; Erphas O; Louga A; Checchi F; Ghabri S; Piola P
PLoS Clin Trials; 2006 Dec; 1(8):e39. PubMed ID: 17160135
[TBL] [Abstract][Full Text] [Related]
56. [The return of sleeping sickness in an epidemic form: international action for drugs].
Kager PA
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2527-30. PubMed ID: 12532663
[TBL] [Abstract][Full Text] [Related]
57. Chemotherapy against human African trypanosomiasis: is there a road to success?
Burri C
Parasitology; 2010 Dec; 137(14):1987-94. PubMed ID: 20961469
[TBL] [Abstract][Full Text] [Related]
58. Treatment perspectives for human African trypanosomiasis.
Bouteille B; Oukem O; Bisser S; Dumas M
Fundam Clin Pharmacol; 2003 Apr; 17(2):171-81. PubMed ID: 12667227
[TBL] [Abstract][Full Text] [Related]
59. Unusual MRI Findings in African
Boukobza M; Lariven S; Houzé S; Laissy JP
Am J Trop Med Hyg; 2020 Jan; 102(1):5-6. PubMed ID: 31971136
[No Abstract] [Full Text] [Related]
60. [Treatment of human trypanosomiasis caused by Trypanosoma brucei gambiense using alpha-difluoromethylornithine. Results in 7 patients].
Taelman H; Marcelis L; Sonnet J; Kazyumba G; Van den Enden E; Wery M; Schechter PJ
Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):578-88. PubMed ID: 3143491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
